Bellerophon Therapeutics Stock Price, News & Analysis (NASDAQ:BLPH)

$2.03 -0.09 (-4.25 %)
(As of 01/16/2018 04:00 PM ET)
Previous Close$2.12
Today's Range$2.02 - $2.14
52-Week Range$0.59 - $2.74
Volume148,200 shs
Average Volume398,078 shs
Market Capitalization$75.42 million
P/E Ratio-1.56
Dividend YieldN/A
BetaN/A

About Bellerophon Therapeutics (NASDAQ:BLPH)

Bellerophon Therapeutics logoBellerophon Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication. Its INOpulse device has a mechanism that delivers brief, targeted pulses of nitric oxide timed to occur at the beginning of a breath for delivery to the alveoli of the lungs, which minimizes the amount of drug required for treatment. The Company's second program, BCM, is a medical device focused to prevent congestive heart failure following a ST Segment Elevation Myocardial Infarction (STEMI), which is a type of severe heart attack. The Company's BCM is in PRESERVATION I clinical trial.

Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorHealthcare
SymbolNASDAQ:BLPH
CUSIPN/A
Phone+1-908-5744770

Debt

Debt-to-Equity RatioN/A
Current Ratio6.15%
Quick Ratio6.15%

Price-To-Earnings

Trailing P/E Ratio-1.56153846153846
Forward P/E Ratio-1.72
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.57 per share
Price / Book3.56

Profitability

Trailing EPS($1.30)
Net Income$-23,810,000.00
Net MarginsN/A
Return on Equity-276.82%
Return on Assets-78.56%

Miscellaneous

Employees20
Outstanding Shares55,180,000

Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics Inc (NASDAQ:BLPH) posted its quarterly earnings results on Tuesday, November, 7th. The biotechnology company reported ($0.22) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.22). View Bellerophon Therapeutics' Earnings History.

When will Bellerophon Therapeutics make its next earnings announcement?

Bellerophon Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Bellerophon Therapeutics.

Where is Bellerophon Therapeutics' stock going? Where will Bellerophon Therapeutics' stock price be in 2018?

2 brokerages have issued 12-month target prices for Bellerophon Therapeutics' stock. Their predictions range from $4.50 to $5.00. On average, they expect Bellerophon Therapeutics' stock price to reach $4.75 in the next twelve months. View Analyst Ratings for Bellerophon Therapeutics.

Who are some of Bellerophon Therapeutics' key competitors?

Who are Bellerophon Therapeutics' key executives?

Bellerophon Therapeutics' management team includes the folowing people:

  • Jonathan M. Peacock, Chairman of the Board, President (Age 59)
  • Fabian Tenenbaum, Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director (Age 42)
  • Assaf Korner, Chief Financial Officer (Age 40)
  • Martin D. Meglasson Ph.D., Chief Scientific Officer, Vice President (Age 65)
  • Reinilde Heyrman M.D., Vice President, Chief Clinical Development Officer and Secretary (Age 54)
  • Martin Dekker, Vice President - Device Engineering (Age 42)
  • Manesh Naidu, Vice President, Chief Business Officer (Age 45)
  • Deborah A Quinn M.D., Vice President - Medical Lead for INOpulse Programs (Age 60)
  • Daniel Tasse, Director (Age 57)
  • Ted Wang Ph.D., Director

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

How do I buy Bellerophon Therapeutics stock?

Shares of Bellerophon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bellerophon Therapeutics' stock price today?

One share of Bellerophon Therapeutics stock can currently be purchased for approximately $2.03.

How big of a company is Bellerophon Therapeutics?

Bellerophon Therapeutics has a market capitalization of $75.42 million. The biotechnology company earns $-23,810,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. Bellerophon Therapeutics employs 20 workers across the globe.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 Liberty Corner Rd Ste 302, WARREN, NJ 07059-6796, United States. The biotechnology company can be reached via phone at +1-908-5744770 or via email at [email protected]


MarketBeat Community Rating for Bellerophon Therapeutics (BLPH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Bellerophon Therapeutics (NASDAQ:BLPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.75$4.75$4.75$4.75
Price Target Upside: 302.54% upside302.54% upside302.54% upside302.54% upside

Bellerophon Therapeutics (NASDAQ:BLPH) Consensus Price Target History

Price Target History for Bellerophon Therapeutics (NASDAQ:BLPH)

Bellerophon Therapeutics (NASDAQ:BLPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/6/2017HC WainwrightReiterated RatingBuy$5.00LowView Rating Details
4/17/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$4.50HighView Rating Details
8/11/2016CowenReiterated RatingBuyN/AView Rating Details
3/22/2016FBR & CoReiterated RatingOutperform$11.00N/AView Rating Details
3/22/2016Leerink SwannLower Price TargetOutperform$11.00 -> $9.00N/AView Rating Details
(Data available from 1/16/2016 forward)

Earnings

Bellerophon Therapeutics (NASDAQ:BLPH) Earnings History and Estimates Chart

Earnings by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Bellerophon Therapeutics (NASDAQ BLPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.24)N/AView Earnings Details
11/7/2017Q3 2017($0.22)($0.22)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.15)($0.12)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.25)($0.15)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.21)($0.37)ViewN/AView Earnings Details
11/8/2016Q3 2016($0.42)($0.30)ViewN/AView Earnings Details
8/9/2016Q216($0.51)($0.39)ViewN/AView Earnings Details
5/10/2016Q116($0.65)($0.54)ViewN/AView Earnings Details
3/21/2016Q4($1.06)($0.82)ViewListenView Earnings Details
11/12/2015Q315($0.94)($0.86)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.96)($0.90)ViewN/AView Earnings Details
5/15/2015Q1 2015($1.25)($1.27)ViewN/AView Earnings Details
3/31/2015Q4 2014($2.16)($1.62)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Bellerophon Therapeutics (NASDAQ:BLPH) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.18 EPS
Next Year EPS Consensus Estimate: $-0.98 EPS

Dividends

Dividend History for Bellerophon Therapeutics (NASDAQ:BLPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Bellerophon Therapeutics (NASDAQ BLPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 60.40%
Institutional Ownership Percentage: 43.51%
Insider Trades by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)
Institutional Ownership by Quarter for Bellerophon Therapeutics (NASDAQ:BLPH)

Bellerophon Therapeutics (NASDAQ BLPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/9/2016Jens LuehringDirectorBuy20,000$0.56$11,200.0039,860View SEC Filing  
5/17/2016Jonathan M PeacockCEOBuy5,000$1.37$6,850.00222,702View SEC Filing  
12/16/2015Jonathan M. PeacockCEOBuy20,300$2.75$55,825.0051,727View SEC Filing  
8/19/2015Jonathan M PeacockCEOBuy5,000$5.48$27,400.0031,427View SEC Filing  
5/20/2015Jonathan M PeacockCEOBuy5,560$8.69$48,316.40View SEC Filing  
2/19/2015Daniel TasseDirectorBuy25,000$12.00$300,000.00View SEC Filing  
2/19/2015Jonathan M PeacockCEOBuy20,800$12.00$249,600.00View SEC Filing  
2/19/2015Linde North America, Inc.Major ShareholderBuy358,916$12.00$4,306,992.00View SEC Filing  
2/19/2015Manesh NaiduInsiderBuy1,500$12.00$18,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Bellerophon Therapeutics (NASDAQ BLPH) News Headlines

Source:
DateHeadline
 Brokerages Set $5.00 Price Target for Bellerophon Therapeutics Inc (BLPH) Brokerages Set $5.00 Price Target for Bellerophon Therapeutics Inc (BLPH)
www.americanbankingnews.com - January 12 at 9:32 AM
Bellerophon Therapeutics (BLPH) Reports First Patient Enrolled in Phase 2b Study Evaluating INOpulse for Treatment ... - StreetInsider.comBellerophon Therapeutics (BLPH) Reports First Patient Enrolled in Phase 2b Study Evaluating INOpulse for Treatment ... - StreetInsider.com
www.streetinsider.com - January 3 at 4:51 PM
Bellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung DiseaseBellerophon Announces First Patient Enrolled in Phase 2b Study Evaluating INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
finance.yahoo.com - January 3 at 9:25 AM
Zacks: Brokerages Anticipate Bellerophon Therapeutics Inc (BLPH) Will Announce Earnings of -$0.24 Per ShareZacks: Brokerages Anticipate Bellerophon Therapeutics Inc (BLPH) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - January 2 at 7:34 AM
Analyzing Bellerophon Therapeutics (BLPH) and Its RivalsAnalyzing Bellerophon Therapeutics (BLPH) and Its Rivals
www.americanbankingnews.com - December 29 at 11:30 PM
Head to Head Analysis: Bellerophon Therapeutics (BLPH) vs. Dynavax Technologies (DVAX)Head to Head Analysis: Bellerophon Therapeutics (BLPH) vs. Dynavax Technologies (DVAX)
www.americanbankingnews.com - December 29 at 3:24 PM
Critical Contrast: Bellerophon Therapeutics (BLPH) vs. The CompetitionCritical Contrast: Bellerophon Therapeutics (BLPH) vs. The Competition
www.americanbankingnews.com - December 27 at 10:00 AM
Zacks: Bellerophon Therapeutics Inc (BLPH) Given $5.00 Consensus Target Price by BrokeragesZacks: Bellerophon Therapeutics Inc (BLPH) Given $5.00 Consensus Target Price by Brokerages
www.americanbankingnews.com - December 26 at 1:10 AM
Bellerophon Therapeutics, Inc. (BLPH) Sees Large Decrease in Short InterestBellerophon Therapeutics, Inc. (BLPH) Sees Large Decrease in Short Interest
www.americanbankingnews.com - December 16 at 2:08 AM
Zacks: Bellerophon Therapeutics, Inc. (BLPH) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Bellerophon Therapeutics, Inc. (BLPH) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 10 at 7:32 AM
Bellerophon Therapeutics (BLPH) & Its Competitors Financial AnalysisBellerophon Therapeutics (BLPH) & Its Competitors Financial Analysis
www.americanbankingnews.com - December 6 at 3:08 PM
Analysts Anticipate Bellerophon Therapeutics, Inc. (BLPH) to Announce ($0.24) Earnings Per ShareAnalysts Anticipate Bellerophon Therapeutics, Inc. (BLPH) to Announce ($0.24) Earnings Per Share
www.americanbankingnews.com - December 3 at 9:46 PM
Bellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of DirectorsBellerophon Appoints Ted Wang, Ph.D., of Puissance Capital Management, to its Board of Directors
finance.yahoo.com - December 1 at 5:25 PM
Zacks: Analysts Anticipate Bellerophon Therapeutics, Inc. (BLPH) Will Announce Earnings of -$0.24 Per ShareZacks: Analysts Anticipate Bellerophon Therapeutics, Inc. (BLPH) Will Announce Earnings of -$0.24 Per Share
www.americanbankingnews.com - November 28 at 7:56 AM
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - November 8 at 5:32 AM
Bellerophon Provides Business Update and Reports Third Quarter 2017 Financial ResultsBellerophon Provides Business Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 7:28 PM
Bellerophon Therapeutics posts 3Q lossBellerophon Therapeutics posts 3Q loss
finance.yahoo.com - November 7 at 7:28 PM
Bellerophon Therapeutics, Inc. (BLPH) Set to Announce Quarterly Earnings on MondayBellerophon Therapeutics, Inc. (BLPH) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 8:50 AM
BRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filingBRIEF-Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
www.reuters.com - October 24 at 11:42 PM
Bellerophon Announces $23 Million Private PlacementBellerophon Announces $23 Million Private Placement
finance.yahoo.com - October 2 at 12:59 PM
Reviewing Recro Pharma (REPH) & Bellerophon Therapeutics (BLPH)Reviewing Recro Pharma (REPH) & Bellerophon Therapeutics (BLPH)
www.americanbankingnews.com - September 28 at 6:16 PM
-$0.22 EPS Expected for Bellerophon Therapeutics, Inc. (BLPH) This Quarter-$0.22 EPS Expected for Bellerophon Therapeutics, Inc. (BLPH) This Quarter
www.americanbankingnews.com - September 13 at 9:30 AM
Bellerophon Therapeutics to Provide Corporate Update at Two Investor ConferencesBellerophon Therapeutics to Provide Corporate Update at Two Investor Conferences
finance.yahoo.com - September 7 at 4:49 PM
Bellerophon Therapeutics, Inc. (BLPH) Receives Buy Rating from HC WainwrightBellerophon Therapeutics, Inc. (BLPH) Receives Buy Rating from HC Wainwright
www.americanbankingnews.com - September 6 at 7:40 AM
Bellerophon Therapeutics (BLPH) Reports Positive Top Line Phase ... - StreetInsider.comBellerophon Therapeutics (BLPH) Reports Positive Top Line Phase ... - StreetInsider.com
www.streetinsider.com - September 5 at 11:13 PM
Bellerophon Therapeutics (BLPH) Reports Positive Top Line Phase 2 Data of INOpulse for Treatment of PH-COPDBellerophon Therapeutics (BLPH) Reports Positive Top Line Phase 2 Data of INOpulse for Treatment of PH-COPD
www.streetinsider.com - September 5 at 6:11 PM
Bellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary DiseaseBellerophon Announces Positive Top Line Phase 2 Data of INOpulse® for Treatment of Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease
finance.yahoo.com - September 5 at 6:11 PM
Bellerophon shares surge 20% premarket on positive results in trial of COPD treatmentBellerophon shares surge 20% premarket on positive results in trial of COPD treatment
finance.yahoo.com - September 5 at 6:11 PM
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Releases  Earnings Results, Beats Expectations By $0.03 EPSBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Releases Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - August 8 at 10:51 AM
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - August 7 at 10:11 PM
Bellerophon Reports Second Quarter 2017 Financial Results and Provides Business UpdateBellerophon Reports Second Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - August 7 at 5:09 PM
Bellerophon Therapeutics posts 2Q lossBellerophon Therapeutics posts 2Q loss
finance.yahoo.com - August 7 at 5:09 PM
Bellerophon (BLPH) Announces FDA Agreement on Phase 2b Study ... - StreetInsider.comBellerophon (BLPH) Announces FDA Agreement on Phase 2b Study ... - StreetInsider.com
www.streetinsider.com - August 5 at 2:58 AM
Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)Bellerophon Announces FDA Agreement on Phase 2b Study Design for INOpulse® in Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
finance.yahoo.com - August 3 at 6:02 PM
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Scheduled to Post Quarterly Earnings on MondayBellerophon Therapeutics, Inc. (NASDAQ:BLPH) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - July 31 at 8:10 AM
Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon TherapeuticsBiotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon Therapeutics
www.bizjournals.com - May 25 at 10:04 PM
Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar ... - PR Newswire (press release)Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar ... - PR Newswire (press release)
www.prnewswire.com - May 25 at 5:01 PM
Bellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse - StreetInsider.comBellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse - StreetInsider.com
www.streetinsider.com - May 24 at 8:53 PM
Bellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulseBellerophon Therapeutics (BLPH) Offers Positive Phase 2 Clinical Data on INOpulse
www.streetinsider.com - May 23 at 11:51 AM
Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Bellerophon Reports First Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - May 15 at 9:41 AM
BRIEF-Bellerophon to issue 2 mln registered shares of common stockBRIEF-Bellerophon to issue 2 mln registered shares of common stock
www.reuters.com - May 11 at 4:29 PM
Bellerophon Therapeutics (BLPH) Enters Agreement for $3M Registered Direct Offering of Common Stock, WarrantsBellerophon Therapeutics (BLPH) Enters Agreement for $3M Registered Direct Offering of Common Stock, Warrants
www.streetinsider.com - May 11 at 9:15 AM
Bellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS - StreetInsider.comBellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS - StreetInsider.com
www.streetinsider.com - May 2 at 11:49 AM
Bellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATSBellerophon Therapeutics (BLPH) to Present Positive Data on INOpulse at ATS
www.streetinsider.com - May 1 at 3:57 PM
Bellerophon Therapeutics (BLPH) Highlights Clinical Data on INOpulse® for Pulmonary Arterial Hypertension at ... - StreetInsider.comBellerophon Therapeutics (BLPH) Highlights Clinical Data on INOpulse® for Pulmonary Arterial Hypertension at ... - StreetInsider.com
www.streetinsider.com - April 7 at 8:34 AM
BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements anBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an
biz.yahoo.com - March 16 at 3:17 PM
APRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBXAPRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX
www.nasdaq.com - March 14 at 8:42 AM
BELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual ReportBELLEROPHON THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
us.rd.yahoo.com - March 13 at 11:49 AM
Bellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business UpdateBellerophon Reports Fourth Quarter 2016 Financial Results and Provides Business Update
us.rd.yahoo.com - March 13 at 11:49 AM
BELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial StatementBELLEROPHON THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement
biz.yahoo.com - March 13 at 11:49 AM

SEC Filings

Bellerophon Therapeutics (NASDAQ:BLPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Bellerophon Therapeutics (NASDAQ:BLPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Bellerophon Therapeutics (NASDAQ BLPH) Stock Chart for Tuesday, January, 16, 2018

Loading chart…

This page was last updated on 1/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.